Clinical Trials
59 trialsNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Sun Yat-sen University
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Shandong Cancer Hospital and Institute
CLEAR-03
Fudan University
FUDOSE
UNICANCER
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Fudan University
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
First Affiliated Hospital of Zhejiang University
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
IMMUNOSTAR
Gruppo Oncologico Italiano di Ricerca Clinica
CATALIS
Shanghai Zhongshan Hospital
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
The First Affiliated Hospital of Anhui Medical University
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
Qilu Hospital of Shandong University
NePHera
Peking Union Medical College Hospital
Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
Asan Medical Center
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer
Xijing Hospital of Digestive Diseases
NO-CUT
Niguarda Hospital
AXOAXI
Helsinki University Central Hospital
REVISE
West China Hospital
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer
Hebei Medical University Fourth Hospital
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Tianjin Medical University Cancer Institute and Hospital
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Harbin Medical University
SUNRISE
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Peking University
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
Sun Yat-sen University
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer
Tang-Du Hospital
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
TESS
Sun Yat-sen University
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Peking University Cancer Hospital & Institute
SIRTCI
Federation Francophone de Cancerologie Digestive
TRACE-LE
Fujian Medical University Union Hospital
NECI
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NICE
Nanfang Hospital, Southern Medical University
Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Third Affiliated Hospital, Sun Yat-Sen University
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Fudan University
Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer
West China Hospital
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
UNC Lineberger Comprehensive Cancer Center
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
China Medical University, China
Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Shanghai Zhongshan Hospital
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
Harbin Medical University
XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
Harbin Medical University
PREPARE
National Cancer Center, Korea
Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
H. Lee Moffitt Cancer Center and Research Institute
SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer
The First People's Hospital of Changzhou